About
338
Publications
36,156
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
33,965
Citations
Introduction
Additional affiliations
September 1996 - present
Publications
Publications (338)
Background:
We aimed to provide a simple, descriptive health-status profile for cancer patients with bone metastases, based on the EuroQol EQ-5D, a tool commonly used to measure health utility scores, and to evaluate its association with the Brief Pain Inventory (BPI), a legacy pain-assessment tool. Although pain is one of five health-status dimen...
Purpose:
To investigate the systematic differences in the self-reporting and valuation of overall health and, in particular, pain/discomfort between three countries (England/UK, Japan, and Spain) on the EQ-5D.
Methods:
Existing datasets were used to explore differences in responses on the EQ-5D descriptive system between Japan (3L and 5L), the U...
Background:
Cachexia is a frequent manifestation of pancreatic cancer, can limit a patient's ability to take chemotherapy, and is associated with shortened survival. We developed a model to predict the early onset of cachexia in advanced pancreatic cancer patients.
Methods:
Patients with newly diagnosed, untreated metastatic or locally advanced...
Background:
Disease-related symptoms impair the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic therapy. Available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in p...
Purpose
Women with breast cancer frequently develop painful bone metastases. This retrospective study was designed to longitudinally characterize patterns of patient-reported symptoms among patients with breast cancer relative to the diagnosis of bone metastases.
Methods
Patient records were identified from the Oncology Services Comprehensive Elec...
Translational cancer research requires a quality-of-life–driven agenda.
BACKGROUND: It has been recognized that symptom burden reported as a patient-reported outcome is valuable in assessment of both disease and treatment-related symptoms and should be incorporated into evaluation of clinical benefit of novel therapies. MDASI-BT is a widely-used instrument for measuring symptom burden in brain tumor patients, and its J...
The objective of the study was to assess the relation between development of cancer- and cancer therapy-induced symptoms, distress, plasma levels of cytokines, and damage-associated molecular patterns (DAMPs) in patients with acute myeloid leukemia (AML; n = 45) receiving remission induction chemotherapy. Patients were monitored for somatic symptom...
Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC). The aim of this study was to evaluate the impact of SREs on patients' pain, analgesic use, and pain interference with...
Cancer-related fatigue is defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. It is one of the most common side effects in patients with cancer. Fatigue has been...
Medullary thyroid cancer (MTC) - related diarrhea can be debilitating, reduces quality of life (QOL) and may be the only indication for initiating systemic therapy. Conventional anti-diarrheal drugs are not always helpful and may have side effects. CASAD, a natural calcium montmorrilonite clay, safely adsorbs toxins and inflammatory proteins associ...
Background: Patients with advanced breast cancer and bone metastases are at an increased risk for experiencing skeletal-related events (SREs), which include pathological fracture (PF), surgery to bone (SB) radiation to bone (RB), and spinal cord compression (SCC). The pain of SREs can be severe enough to interfere with daily functioning. Here we ev...
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients. The most commonly used pain assessment instruments are visual analogue scales, a single-item measure, and the Brief Pain Inventory Qu...
The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting
using the National Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE). Because this approach
underdetects symptomatic AEs, the NCI issued two contracts to create a patient-reported outcome (...
Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. There are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin inhibits pathological pain following nerve injury in mice and rats. We tested the hyp...
Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. At present, there are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin is the most widely used prescription drug in the world and improves glyce...
Context:
Cancer patients frequently suffer from various symptoms often impairing functional status and quality of life. To enable timely supportive care, these symptoms must be assessed adequately with reliable tools.
Objectives:
This study aimed to validate the German version of the M. D. Anderson Symptom Inventory (MDASI).
Methods:
This was...
Background:
Giant cell tumor of bone (GCTB) is an aggressive primary osteolytic tumor. GCTB often involves the epiphysis, usually causing substantial pain and functional disability. Denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κΒ ligand (RANKL), is an effective treatment option for patients with advance...
Purpose:
Women with breast cancer frequently develop painful bone metastases. This retrospective study was designed to longitudinally characterize patterns of patient-reported symptoms among patients with breast cancer relative to the diagnosis of bone metastases.
Methods:
Patient records were identified from the Oncology Services Comprehensive...
12 Background: Patients with castration-resistant prostate cancer (CRPC) and bone metastases (BM) may experience debilitating pain that impacts daily functioning and diminishes the quality of life. Previous results from a phase III trial demonstrated superiority of denosumab to ZA in delaying or preventing skeletal-related events (pathological frac...
The Patient-Reported Outcomes Safety Event Reporting (PROSPER) Consortium was convened to improve safety reporting by better incorporating the perspective of the patient. PROSPER comprises industry, regulatory authority, academic, private sector and patient representatives who are interested in the area of patient-reported outcomes of adverse event...
Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with prednisone alone. We describe analyses of data for patient-reported pain and functional status in a preplanned interim...
Patients with colorectal cancer (CRC) report debilitating fatigue that is caused by both disease and chemotherapy. An inflammatory mechanism for fatigue and affective symptoms has been proposed in cancer patients. This prospective study investigated tryptophan and tyrosine metabolism and symptom severity in 33 CRC patients undergoing oxaliplatin-ba...
This analysis evaluated patient-reported outcomes and analgesic use in patients with bone metastases from solid tumours across three comparative studies of denosumab and zoledronic acid.
Pooled data were analysed from three identically designed double-blind phase III studies comparing subcutaneous denosumab 120 mg with intravenous zoledronic acid 4...
Pain is a common symptom associated with cancer and its treatment. Pain management is an important aspect of oncologic care, and unrelieved pain significantly comprises overall quality of life. These NCCN Guidelines list the principles of management and acknowledge the range of complex decisions faced in the management oncologic pain. In addition t...
Introduction
Risk factors for employment difficulties after cancer diagnosis are incompletely understood, and interventions to improve post-cancer employment remain few. New targets for intervention are needed.
Methods
We assessed a cohort of 530 nonmetastatic cancer patients (aged ≤ 65 years, >6 months from diagnosis, off chemo- or radiotherapy) f...
Abstract # 603
BACKGROUND
Few studies have examined the acute effects of autologous hematopoietic stem cell transplantation (Au-HSCT) on the neuropsychological functioning of patients with multiple myeloma (MM). The prevalence of cognitive deficits after induction chemotherapy (pre-AuHSCT) was examined in patients with MM, clinically significant c...
Background
Fatigue is a common, debilitating side-effect of prostate cancer and its treatment. Patient-reported fatigue was evaluated as part of COU-AA-301, a randomized, placebo-controlled, phase III trial of abiraterone acetate and prednisone versus placebo and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients after d...
BACKGROUND
In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases.
METHODS
The prevention of pain, reduction in pain interference with daily life activities, and the proportion of patients requiring strong opioid analgesics were assessed in a rand...
During the first month after autologous hematopoietic stem cell transplant (ASCT), patients with multiple myeloma (MM) often suffer from fatigue, pain, disturbed sleep, drowsiness, and poor appetite. These symptoms can be triggered by residual disease, high-dose chemotherapy. We explored temporal associations between activation of the cytokine netw...
Background
Androgen deprivation therapy (ADT) is the standard treatment of hormone-sensitive metastatic prostate cancer (HSMPC). We performed a phase III multicentre trial to compare ADT alone with ADT plus docetaxel (D) in HNMPC.
Methods
Patients (pts) with HSMPC were randomly assigned to either arm A (ADT + D: 75mg/m q3w, up to 9 cycles) or arm...
Background
AA is a potent, selective androgen biosynthesis inhibitor. The impact of AA on pain and functional status was prospectively evaluated as part of a large phase 3 trial in asymptomatic/mildly symptomatic, progressive, chemotherapy-naïve mCRPC.
Material and methods
COU-AA-302 is an international, randomized, double-blind study of AA (1 g d...
Background
Patients with metastatic bone disease are living longer in the metastatic stage due to improvements in cancer therapy, making strategies to prevent the aggravation of bone disease and its complications, such as skeletal-related events (SREs) and pain, increasingly important.Patients and resultsIn this phase 3 trial in patients with advan...
Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health ef...
Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health ef...
Pain is prevalent among patients with cancer, yet pain management patterns in outpatient oncology are poorly understood.
A total of 3,123 ambulatory patients with invasive cancer of the breast, prostate, colon/rectum, or lung were enrolled onto this prospective study regardless of phase of care or stage of disease. At initial assessment and 4 to 5...
Background: Skeletal-related events (SREs), which include pathologic fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC), occur frequently in patients with bone metastases and can lead to debilitating clinical consequences such as functional impairment and bone pain. Denosumab (XGEVA®) is a fully human mon...
Spinal stereotactic body radiation therapy (SBRT) is increasingly used to manage spinal metastases, yet the technique's effectiveness in controlling the symptom burden of spinal metastases has not been well described. We investigated the clinical benefit of SBRT for managing spinal metastases and reducing cancer-related symptoms.
149 patients with...
Background The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting system is widely used
by clinicians to measure patient symptoms in clinical trials. The European Organization for Research and Treatment of Cancer's
Quality of Life core questionnaire (EORTC QLQ-C30) enables cancer patients to rate their...
Background: Bone metastases in patients with advanced cancer commonly cause pain and can lead to skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody against RANK Ligand that delayed or prevented SREs more effectively than ZA in patients with solid tumors and bone metastases in a randomized phase 3 clinical trial (Henry D...
Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor (PBT) patients. Development of disease-related symptoms is predictive of tumor recurrence in other cancers but has not been reported in the PBT population.
A cross-sectional sample of 294 PBT patients participated. Pr...
5539 Background: Long-term patient reported symptom burden data is lacking and required for the adequate support of OPCa survivors. The long-term impact of IMRT has not been evaluated. Methods: A cross sectional study of 122 OPCa patients in remission treated at a single institution since 2000 was performed using the M. D. Anderson Symptom Inventor...
9094 Background: Oxaliplatin-based chemotherapy (FOLFOX or FOLFIRI), a standard first-line chemotherapy for patients with colorectal cancer (CRC), is not only associated with dose-limiting toxicity, such as cumulative sensory neuropathy, but also with debilitating general symptom burden, such as fatigue, pain, and distress. The lack of effective me...
e19545 Background: A major barrier to effective symptom management in chronic myeloid leukemia (CML) is inadequate assessment. We aimed to develop a short, easily-understood, valid, and reliable patient-reported outcome measure of CML symptoms for research and practice. Methods: 127 patients with CML completed the 13 symptom severity and 6 interfer...
e16594 Background: The aim of this study is to define the content domain for a patient-reported outcome (PRO) measure of gastrointestinal stromal tumor (GIST) symptom burden. Symptom burden, defined as the combined impact of symptoms and treatment on daily functioning, can be an effective endpoint in clinical trials to establish treatment benefits....
e19627 Background: Patients with multiple myeloma (MM) undergoing induction therapy experience both disease- and therapy-related symptoms. This study selectively focused on the trajectory of pain, fatigue, numbness and bone aches from patient-reported outcome. Methods: MM patients (N=62) repeatedly rated symptoms via the M. D. Anderson Symptom Inve...
5523 Background: Previously we reported that 1/3 of patients had moderate to severe (MS) levels of fatigue 2 months after completing radiation therapy (RT) or chemoradiation (CRT) for head and neck cancer (HNC) as measured by the M. D. Anderson Symptom Inventory – Head and Neck Module (MDASI-HN). However, the rate and severity of patient-reported f...
In a recently completed trial of breast cancer patients with bone metastases, denosumab, a fully human monoclonal anti-RANKL antibody, was superior to zoledronic acid (ZA) in delaying/preventing skeletal-related events. Between-treatment differences in patient-reported pain interference with daily functioning were assessed.
Eligible breast cancer p...
Background About one in three breast cancer patients undergoing treated with aromatase inhibitors report problems with joint pain, some times interfering with work and other activities. We conducted a longitudinal study to characterize the course and impact of arthralgia and other symptoms during anastozole therapy by following how pain and other s...
1. IntroductionEvidence of the efficacy of analgesic treatments is typicallybased on double-blind randomized clinical trials (RCTs) conductedin patients with a specific pain diagnosis, disease, or condition[1,2,9–11,40]. The results of these RCTs provide evidence of effi-cacy in the specific condition investigated, especially when thereis replication o...
551
Background: Neuropathy attributed to oxaliplatin-based chemotherapy is a dose limiting factor in the administration of chemotherapy. With premising clinical outomes, bevacizumab (BV) has been added with colorectal cancer (CRC) patients in first line and second- line therapy. Although toxicity been well documented, there is no evidence of the im...
We aimed to determine the smallest changes in health-related quality of life (HRQoL) scores in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 and the Brain Cancer Module (QLQ-BN20), which could be considered as clinically meaningful in brain cancer patients.
World Health Organisation performance...